Declaration of interests IL has received grants from Boehringer Ingelheim, Dexcom, Eli Lilly, Novo Nordisk, Roche, and Pfizer, with all payments made to her institution; has received payment or honoraria from AbbVie, Altimmune, Alveus Therapeutics, Amgen, Antag Therapeutics, AstraZeneca, Bayer, Betagenon, Bioio, Biomea, Boehringer Ingelheim, Carmot, Cytoki Pharma, Eli Lilly, Intercept, Janssen/J&J, Juvena, Keros Therapeutics, Mediflix, Merck, Metsera, Neurocrine, Novo Nordisk, Pharmaventures, Pfizer, Regeneron, Roche, Sanofi, Shionogi, Source Bio, Structure Therapeutics, TARGET RWE, Terns Pharma, The Comm Group, Verdiva Bio, WebMD, and Zealand Pharma; and has received support to attend meetings from AstraZeneca, Boehringer Ingelheim, Novo Nordisk, and Eli Lilly. SJB is a full-time employee of, and has received gifts from, Novo Nordisk and holds an unpaid affiliation with the University of Copenhagen. JBB has received grants or consulting fees, or both, from Altimmune, Antag, Amgen, ApStem, Aqua Medical, AstraZeneca, Boehringer Ingelheim, CeQur, Corcept Therapeutics, Dexcom, Eli Lilly, embecta, GentiBio, Glyscend, Insulet, Medtronic MiniMed, Mellitus Health, Metsera, Novo Nordisk, Pendulum Therapeutics, Praetego, Stability Health, Tandem, Terns, Vertex, and Zealand, with all payments made to his institution; has received payment for expert testimony from Medtronic MiniMed and Novo Nordisk, with all payments made to his institution; has participated on a data safety monitoring board or advisory board for Altimmune, AstraZeneca, and Tandem Diabetes Care; holds stock or options in Glyscend, Mellitus Health, Metsera, Pendulum Therapeutics, Praetego, and Stability Health; and has an unpaid leadership role for the Association for Clinical and Translational Science. PF has received payment or honoraria from Amryt, Bial, Boehringer Ingelheim, FaesFarma, Janssen, Lilly, Merck, Novartis, Novo Nordisk, Pronokal, and Sanofi, along with support to attend meetings from Bial, Medinfar, Novo Nordisk, and Sanofi. WTG has received grants as a principal investigator from Novo Nordisk, Eli Lilly & Co, Pfizer, Epitomee, Neurovalens, Zealand, Carmot/Roche, Terns Pharmaceuticals, and Viking Therapeutics; has received grants for research from the UAB Diabetes Research Center (DK079626) funded by the US National Institutes of Health (NIH) and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), with all payments made to his institution; has received consulting fees as an advisory board member from Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Pfizer, Fractyl Health, Alnylam Pharmaceuticals, Inogen, Zealand, Allurion, Carmot/Roche, Terns Pharmaceuticals, Neurocrine, Keros Therapeutics, Gan & Lee, NodThera, and Regeneron; has received fees to participate on a data safety monitoring board or advisory board for Boehringer Ingelheim and Eli Lilly; and is an unpaid member for the Lancet Commission on Obesity, American Association of Clinical Endocrinology (AACE) update of obesity treatment algorithm, American Diabetes Association (ADA) nutrition recommendations update, and ADA Standards of Care for Obesity. NMHL and KS are full-time employees of, and hold shares in, Novo Nordisk. JR has received research grants from Amgen, Applied Therapeutics, AstraZeneca, Biomea Fusion, Boehringer Ingelheim, Carmot, Corcept, Eli Lilly, Hanmi, Merck, Novartis, Novo Nordisk, Oramed, Regeneron, Pfizer, Sanofi, Structure Therapeutics, and TERNS; and has served on scientific advisory boards and received honorarium or consulting fees from Amgen, Applied Therapeutics, Biomea Fusion, Eli Lilly, Hanmi, Novo Nordisk, Oramed, Regeneron, Regor, Roche, Sanofi, Structure Therapeutics, and TERNS; and received honoraria for lectures from Eli Lilly, Novo Nordisk, and Sanofi. SW has received payment or honoraria from AstraZeneca, Bausch Health Canada, Boehringer Ingelheim, Eli Lilly, Metsera, Neurogastrix, Novo Nordisk, and Regeneron for academic talks to colleagues; has been provided with medical writing support from AstraZeneca, Boehringer Ingelheim, Bausch Health Canada, Eli Lilly, and Novo Nordisk; and has an unpaid leadership role in The Obesity Society and Obesity Canada.
PubMed
